Table 2.
Arrhythmias prevalence using Random Effect Meta-Analysis
| Type of arrhythmia | Treatment | Number of studies | Prevalence% | Confidence interval 95% (CI%95) | Heterogeneity index I2 (%) | P value |
|---|---|---|---|---|---|---|
| Ventricular tachycardia | Magnesium | 7 | 5.67 | 1.38–11.97 | 71.81 | 0.003 |
| placebo | 7 | 15.04 | 6.47–26.06 | 88.9 | 0.00 | |
| Ventricular fibrillation | Magnesium | 7 | 2.13 | 0.00–6.59 | 76.81 | 0.00 |
| Placebo | 7 | 4.43 | 0.31–11.69 | 86.09 | 0.00 | |
| Total of Ventricular arrhythmia | Magnesium | 13 | 11.88 | 6.71–18.17 | 82.99 | 0.00 |
| Placebo | 13 | 24.24 | 14.52–35.43 | 92.11 | 0.00 | |
| Atrial fibrillation | Magnesium | 9 | 9.72 | 3.31–18.63 | 92.15 | 0.00 |
| Placebo | 9 | 22.37 | 15.86–29.59 | 85.3 | 0.00 | |
| Supraventricular tachycardia | Magnesium | 6 | 4.90 | 0.84–11.28 | 75.36 | 0.00 |
| Placebo | 6 | 14.62 | 7.26–23.82 | 78.76 | 0.00 | |
| Magnesium | 14 | 10.36 | 5.55–16.32 | 87.16 | 0.00 | |
| Total of supraventricular arrhythmia | Placebo | 14 | 23.91 | 18.82–29.38 | 75.10 | 0.00 |
| Bradycardia | Magnesium | 4 | 6.46 | 0.71–12.21 | 78.9 | 0.00 |
| Placebo | 4 | 7.2 | 1.03–1.37 | 79.8 | 0.00 | |
| Total Arrhythmia | Magnesium | 22 | 41 | 11.44–21.0 | 85.89 | 0.00 |
| Placebo | 22 | 30.85 | 25.07–39.63 | 86.21 | 0.00 |